Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Annexon, Inc.NASDAQ: ANNX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $35.79M fell 25.7% year over year, behind the +17.5% change in trailing-twelve-month research & development. Sequentially, it fell 16.1% from the prior quarter. Over 3 fiscal years it compounded at +18.0% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.7% toward the trailing-twelve-month pace of +17.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 184.7M USD
- Year-over-year change
- +54.6%
- 4-year CAGR
- +16.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 184.7M | +54.6% |
| FY2024 | 2024-12-31 | 119.45M | +5.0% |
| FY2023 | 2023-12-31 | 113.76M | +1.1% |
| FY2022 | 2022-12-31 | 112.5M | +12.4% |
| FY2021 | 2021-12-31 | 100.07M | — |
Research & Development vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.5% is the 3rd highest of 11, against a peer median of -13.1%.
- Over three fiscal years its annual growth of +18.0% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M USD | +16.2% | +41.8% | 6608.2% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M USD | -8.7% | +56.3% | 4685.4% |
| LTM Jun 2026 | $255.77M USD | +11.4% | +6.3% | 243.6% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $96.67M USD | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $15.25M USD | -66.4% | -18.8% | 28.4% | |
| Peer median (excluding ANNX) | — | -13.1% | +3.0% | 677.9% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 3.45M | 3.69M |
| Gross Profit | 0 | 0 | 0 | (3.45M) | (3.69M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 100.07M | 112.5M | 113.76M | 119.45M | 184.7M |
| Selling, General & Admin | 30.65M | 30.95M | 28.02M | 34.63M | 31.71M |
| Operating Expenses | 130.71M | 145.6M | 143.72M | 150.62M | 212.72M |
| Depreciation & Amortization | 2.14M | 2.15M | 2.15M | 3.45M | 2.65M |
| EBITDA | (128.18M) | (139.8M) | (132.09M) | (134.75M) | (204.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (130.71M) | (145.6M) | (143.72M) | (154.07M) | (216.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Income Before Tax | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| EPS (Diluted) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| Weighted Avg Shares | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
| Weighted Avg Shares (Diluted) | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.